A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies.
Cancer Chemother. Pharmacol., Jun;57(6):789-95 (2006)
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
Anticancer Drugs., Apr;19(4):411-20 (2008)
A pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies.
Leuk. Res., Dec;32(12):1842-8 (2008)
Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia.
Clin. Cancer Res., Nov;14(22):7564-8 (2008)
miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation.
Exp. Hematol., Feb;37(2):245-55 (2009)
Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression.
Biochem. Biophys. Res. Commun., Apr;394(3):606-11 (2010)
Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor ÎºB pathways.
Haematologica., Aug;97(8):1255-63 (2012)
Use of recombinant viruses to assess the pattern of early human immunodeficiency virus breakthrough infection in the presence of stavudine.
J. Gen. Virol., Sep;80 ( Pt 9):2361-7 (1999)
Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells.
Blood., Nov;94(10):3499-508 (1999)
Adenovirus infection of primary malignant lymphoid cells.
Leuk. Lymphoma., Jan;43(1):37-49 (2002)
Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate.
Clin. Cancer Res., Aug;8(8):2512-8 (2002)
Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma.
J. Clin. Oncol., Oct;21(20):3785-91 (2003)
Complications of malignancy: case 2. Infectious tissue pneumatosis as a result of colon cancer perforation in a survivor of Hodgkin's disease.
J. Clin. Oncol., Jan;22(2):373-4 (2004)
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced dual-specificity phosphatase expression and AML cell survival.
Leuk. Res., Oct;29(10):1171-9 (2005)
Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression
Biochemical and Biophysical Research Communications
Acute myelogenous leukemia and myelodysplasia secondary to breast cancer treatment: case studies and literature review
The American Journal of the Medical Sciences
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
Journal of Clinical Oncology
Indolent T-lymphoblastic proliferation in Castleman lymphadenopathy
Leukemia and Lymphoma
miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation